The IASLC World Conference on Lung Cancer (WCLC 2026) is the leading global congress dedicated to significantly improving the diagnosis, treatment, and comprehensive care of patients battling lung cancer and other thoracic malignancies. Organized by the esteemed International Association for the Study of Lung Cancer (IASLC), this essential event serves as a critical platform for professionals across medical services, scientific research, and the pharmaceutical industry. Participants will immerse themselves in cutting-edge research, discover innovative therapeutic approaches, and explore best practices in patient management. With an anticipated attendance of over 7,000 international delegates hailing from more than 100 countries, and showcasing over 2,300 groundbreaking abstracts, WCLC 2026 fosters unparalleled opportunities for global collaboration, networking, and the vital exchange of knowledge. Join this influential gathering in Seoul, South Korea, to contribute to and benefit from the latest advancements at the forefront of lung cancer research and clinical practice, ultimately driving forward the mission to enhance patient outcomes worldwide.
Highlights
4 items
01
Globally Recognized Congress
The WCLC is a globally recognized event by the IASLC, focusing on lung cancer and thoracic malignancies.
02
Extensive International Participation
Expect over 7,000 international attendees and delegates from more than 100 countries, fostering global collaboration.
03
Cutting-Edge Research Showcase
The conference will feature over 2,300 abstracts, presenting the latest advancements in diagnosis and treatment.
04
Dedicated Lung Cancer Focus
Specifically targets improving diagnosis, treatment, and care for patients with lung cancer and other thoracic malignancies.
FAQ
4 questions
The conference will be held from September 12 to September 15, 2026, at the COEX Convention & Exhibition Center in Seoul, South Korea.
The event is organized by the International Association for the Study of Lung Cancer (IASLC).
The conference is focused on improving the diagnosis, treatment, and care of patients with lung cancer and other thoracic malignancies.
Projections indicate over 7,000 international attendees and delegates from more than 100 countries, featuring over 2,300 abstracts.
